WO2008038304A2 - Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. - Google Patents
Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. Download PDFInfo
- Publication number
- WO2008038304A2 WO2008038304A2 PCT/IN2007/000436 IN2007000436W WO2008038304A2 WO 2008038304 A2 WO2008038304 A2 WO 2008038304A2 IN 2007000436 W IN2007000436 W IN 2007000436W WO 2008038304 A2 WO2008038304 A2 WO 2008038304A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- scavenger
- nitric oxide
- therapeutic formulation
- complexated
- combined
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- TITLE THERAPEUTIC FORMULATION COfWPRISING OF AN ALPHAGLUCOSIDASE INHIBITOR AND NITRIC OXIDE RELEASING MOIETY COMPLEXATED WITH A NITRIC OXIDE SCAVENGER
- the present invention belongs to the field of pharmaceutical technology and relates to a pharmaceutical composition that aims at combating secondary complications in diabetes drug intake and optimizes the therapeutic usefulness of Oral Hypoglycemic Agents called Alphaglucosidase Inhibitors, which would include Acarbose and Miglitol and comprises of the unique advantage of Nitric Oxide Releasing moiety, which is further complexated with a Nitric Oxide Scavenger.
- Alphaglucosidase Inhibitors which would include Acarbose and Miglitol and comprises of the unique advantage of Nitric Oxide Releasing moiety, which is further complexated with a Nitric Oxide Scavenger.
- the therapeutic edge of this invention would be minimizing the risk of Diabetic Complications due to the Oxidative Cellular Damage produced by Nitric Oxide.
- Nitric Oxide Scavenger has been complexated to reduce the NO levels and hence enhance the safety profile of the products on a long-term use.
- Nitric Oxide one of the most important biological molecules, which is capable of producing several cellular responses, both beneficial as well as detrimental.
- Metabolic Disorders with an inevitable nexus with Cardiovascular Diseases pose one of the biggest threat to the Scientific Community, contributing to one of the highest number of deaths in populations across the globe.
- the most important triggering factor appears to be the changes in the lifestyle and dietary pattern, for the onset of the disease in the individuals.
- the secondary complications are primarily due to factors that are quite unlikely to be noticed. It's precisely because of this reason that Diabetes is often referred to as a "Silent Killer", with a potential damage to the vital organs.
- Macro- and microvascular diseases are the most common causes of morbidity and mortality in patients with diabetes mellitus.
- Diabetic cardiovascular dysfunction represents a problem of great clinical importance underlying the development of various severe complications including retinopathy, nephropathy, neuropathy and increase the risk of stroke, hypertension and myocardial infarction.
- Hyperglycemic episodes which complicate even well controlled cases of diabetes, are closely associated with increased oxidative and nitrosative stress, which can trigger the development of diabetic complications.
- Hyperglycemia stimulates the production of advanced glycosylated end products, activates protein kinase C, and enhances the polyol pathway leading to increased Superoxide anion formation.
- nitrosative stress and peroxynitrite interacts with nitric oxide, forming the potent cytotoxin peroxynitrite, which attacks various biornolecules in the vascular endothelium, vascular smooth muscle and myocardium, leading to cardiovascular dysfunction.
- the pathogenetic role of nitrosative stress and peroxynitrite, and downstream mechanisms including poly(ADP-ribose) polymerase (PARP) activation is not limited to the diabetes-induced cardiovascular dysfunction, but also contributes to the development and progression of diabetic nephropathy, retinopathy and neuropathy. Accordingly, neutralization of peroxynitrite or pharmacological inhibition of PARP is a promising new approach in the therapy and prevention of diabetic complications. Thus it would be important to determine the role of nitrosative stress and downstream mechanisms including activation of PARP in diabetic complications and evolve novel therapeutic strategies such as neutralization of peroxynitrite and inhibition of PARP
- This "causal" therapy would also be associated with other promising tools such as LY 333531 , PJ34, and FP15, which block the protein kinase ⁇ isoform, poly(ADP-ribose) polymerase, and peroxynitrite, respectively.
- Insulin action is initiated through its binding to the cell surface receptor, initiating a series of signal transduction reactions, which stimulate various effectors to produce its physiological effects. Therefore, impairment of insulin signal transduction results in attenuation of insulin action and leads to insulin resistance resulting in type 2 diabetes mellitus. Because the molecular mechanisms of insulin resistance are still being elucidated, it is indispensable to establish in vitro models of basal and insulin-mediated signal transduction to clarify these mechanisms and suggest treatments where appropriate. Evidence demonstrates that exogenously administered nitric oxide (NO) can induce insulin resistance in skeletal muscle.
- NO nitric oxide
- NO nitric oxide
- Endothelium derived nitric oxide is synthesized from the amino acid L- arginine by the endothelial isoform of nitric oxide synthase (NOS), yielding L-citrulline as a byproduct.
- NOS nitric oxide synthase
- Nitric oxide is labile with a short half- life ( ⁇ 4 seconds in biological solutions). It is rapidly oxidised to nitrite and then nitrate by oxygenated haemoglobin before being excreted into the urine.
- co-factors are required for nitric oxide biosynthesis.
- nitric oxide diffuses across the endothelial cell membrane and enters the vascular smooth muscle cells where it activates guanylate cyclase, leading to an increase in intracellular cyclic Guanosine-3',5-Monophosphate (cGMP) concentrations4.
- cGMP mediates many of the biological effects of nitric oxide including the control of vascular tone and platelet function.
- nitric oxide has other molecular targets, which include haem, or other iron centred proteins, DNA, and thiols. These additional reactions may mediate changes in functions of certain key enzymes or ion channels. Nitric oxide also interacts with enzymes of the respiratory chain including complex I and II, and aconitase, and through these effects alters tissue mitochondrial respiration. Interaction of nitric oxide with superoxide anion can attenuate physiological responses mediated by nitric oxide and produce irreversible inhibitory effects on mitochondrial function as a result of the formation of peroxynitrite (ONOO-), a powerful oxidant species.
- ONOO- peroxynitrite
- NOSs are the only enzymes known to simultaneously require five bound cofactors/prosthetic groups: FAD, FMN, haem, tetrahydrobiopterin (BH4) and Ca2+-calmodulin (CaM).
- FAD fluorescence deficiency deficiency deficiency deficiency deficiency deficiency deficiency deficiency deficiency deficiency deficiency deficiency deficiA or NOS2A and Ca2+-calmodulin (CaM).
- nNOS or NOS1 neuronal
- iNOS or NOS2 cytokine inducible
- eNOS or NOS3 endothelial endothelial endothelial endothelial fibros or NOS3
- NO nitric oxide
- NO donor drugs are used in the treatment of hypotension and angina where abnormalities in the L- arginine-nitric oxide pathway have been implicated.
- Overproduction of NO has been associated with a number of disease states including septic shock, inflammatory diseases, diabetes and its complications, ischaemia-reperfusion injury, adult respiratory distress syndrome, neurodegenerative diseases and allograft rejection.
- NO is produced by a group of enzymes, the nitric oxide synthases.
- NO scavenger molecules have demonstrated pharmacological activity in disease models, particularly models of septic shock. These include organic molecules such as PTIO (2-pheny]-4,4,5,5-tetramethylimidazoline-1-oxy!-3-oxide), haemoglobin derivatives such as the pyridoxalated haemoglobin polyoxyethylene conjugate (PHP), low molecular weight iron compounds of diethylenetriaminepentaacetic acid and diethyldithiocarbamate and ruthenium polyaminocarboxylate complexes.
- PDP pyridoxalated haemoglobin polyoxyethylene conjugate
- iron compounds of diethylenetriaminepentaacetic acid and diethyldithiocarbamate and ruthenium polyaminocarboxylate complexes.
- An Objective of this invention is to treat Diabetes and prevent its complications by providing the Oral Hypoglycemic Agents, commonly known as, "Alphaglucosidase- Inhibitors".
- the invention embodies in itself the Claim for separate and individual drugs, that would include Acarbose and Miglitol as separate entities and separate set of inventions
- Another Objective of this invention is to prevent the Diabetic complications produced due to excessive nitrosative stress by mitigating the deleterious effects of NO, with the combination/complexation of the Antidiabeti drugs with the NO scavengers, which would include PTIO, PHP, low molecular weight iron compounds of diethylenetriarninepentaacetic acid, diethyldithiocarbamate or ruthenium polyaminocarboxylate complexes or any other suitable NO scavenger
- Another objective of this invention is to develop useful and convenient dosage levels and forms of such a combination therapeutic.
- Yet another objective of this invention is to enhance individual effects of the components of this composition by their combination.
- the invention embodies in itself 2 separate entities, each belonging to the class of drugs known as "Alphaglucosidase Inhibitors". Further, each active ingredient from the said class has been combined or complexated with NO Scavenger to prevent Diabetic Complications arising out of
- the active ingredients are Alphaglucosidase Inhibitors, which block the action of alpha-glucosidase enzymes at the. brush border of the intestine.
- the inactive ingredients are more or less the same for each of the compound: microcrystalline cellulose or hydroxypropyl methylcellulose, colloidal silicon dioxide, Magnesium stearate, Sodium, Starch, PEG and other appropriate agents
- Alphaglucosidase Inhibitors slows the breakdown of dietary oligosaccharides and disaccharides.
- the delayed digestion of carbohydrates decreases post-prandial glucose concentrations.
- alpha-glucosidase inhibitors lower FPG by 20 to 30 mg/dl and hemoglobin A 1c by 0.7 to 1 %.
- acarbose and miglitol decrease post-prandial glucose by 30 to 70 mg/dl.
- Acarbose and Miglitol have minimal effect on cholesterol and body weight.
- compositions are as follows: 1. Acarbose 25 to 100 mg per day in combination or complexated with NO-Scavenger
Abstract
A therapeutic formulation comprising of Alphaglucosidase Inhibitors as active agents namely, Acarbose and Miglitol, characterized in that said Alphaglucosidase Inhibitors are combined or complexated with NO Scavenger to prevent Diabetic Complications arising out of Nitrosative stress.
Description
TITLE: THERAPEUTIC FORMULATION COfWPRISING OF AN ALPHAGLUCOSIDASE INHIBITOR AND NITRIC OXIDE RELEASING MOIETY COMPLEXATED WITH A NITRIC OXIDE SCAVENGER
Field of Invention
The present invention belongs to the field of pharmaceutical technology and relates to a pharmaceutical composition that aims at combating secondary complications in diabetes drug intake and optimizes the therapeutic usefulness of Oral Hypoglycemic Agents called Alphaglucosidase Inhibitors, which would include Acarbose and Miglitol and comprises of the unique advantage of Nitric Oxide Releasing moiety, which is further complexated with a Nitric Oxide Scavenger. The therapeutic edge of this invention would be minimizing the risk of Diabetic Complications due to the Oxidative Cellular Damage produced by Nitric Oxide. Besides, Nitric Oxide Scavenger has been complexated to reduce the NO levels and hence enhance the safety profile of the products on a long-term use.
Background of the Invention
The most important causes of Diabetic Complications appear to be: a) Auto-oxidation of Glucose; b) Induction and activation of various Lipoxygenase enzymes; c) Activation of Glycation pathways; d) Promotion of the interaction of the Nitric Oxide with superoxide anions to produce peroxynitrite and hydroxyl radicals and e) Reduction of the activity of the Antioxidant defense mechanisms. The major attributing factor for this large scale damage has been identified as Nitric Oxide,
one of the most important biological molecules, which is capable of producing several cellular responses, both beneficial as well as detrimental.
Metabolic Disorders with an inevitable nexus with Cardiovascular Diseases, pose one of the biggest threat to the Scientific Community, contributing to one of the highest number of deaths in populations across the globe. The most important triggering factor appears to be the changes in the lifestyle and dietary pattern, for the onset of the disease in the individuals. However, the secondary complications are primarily due to factors that are quite unlikely to be noticed. It's precisely because of this reason that Diabetes is often referred to as a "Silent Killer", with a potential damage to the vital organs.
Macro- and microvascular diseases are the most common causes of morbidity and mortality in patients with diabetes mellitus. Diabetic cardiovascular dysfunction represents a problem of great clinical importance underlying the development of various severe complications including retinopathy, nephropathy, neuropathy and increase the risk of stroke, hypertension and myocardial infarction. Hyperglycemic episodes, which complicate even well controlled cases of diabetes, are closely associated with increased oxidative and nitrosative stress, which can trigger the development of diabetic complications. Hyperglycemia stimulates the production of advanced glycosylated end products, activates protein kinase C, and enhances the polyol pathway leading to increased Superoxide anion formation. Superoxide anion interacts with nitric oxide, forming the potent cytotoxin peroxynitrite, which attacks various biornolecules in the vascular endothelium, vascular smooth
muscle and myocardium, leading to cardiovascular dysfunction. The pathogenetic role of nitrosative stress and peroxynitrite, and downstream mechanisms including poly(ADP-ribose) polymerase (PARP) activation, is not limited to the diabetes-induced cardiovascular dysfunction, but also contributes to the development and progression of diabetic nephropathy, retinopathy and neuropathy. Accordingly, neutralization of peroxynitrite or pharmacological inhibition of PARP is a promising new approach in the therapy and prevention of diabetic complications. Thus it would be important to determine the role of nitrosative stress and downstream mechanisms including activation of PARP in diabetic complications and evolve novel therapeutic strategies such as neutralization of peroxynitrite and inhibition of PARP
Evidence implicates hyperglycemia-denved oxygen free radicals as mediators of diabetic complications. However, intervention studies with classic antioxidants, such as vitamin E, failed to demonstrate any beneficial effect. Recent studies demonstrate that a single hyperglycemia-induced process of overproduction of Superoxide by the mitochondrial electron-transport chain seems to be the first and key event in the activation of all other pathways involved in the pathogenesis of diabetic complications. These include increased polyol pathway flux, increased advanced glycosylation end product formation, activation of protein kinase C, and increased hexosamine pathway flux. Superoxide overproduction is accompanied by increased nitric oxide generation; due to an endothelial NOS and inducible NOS uncoupled state, a phenomenon favoring the formation of the strong oxidant peroxynitrite, which in turn damages DNA. DNA damage is an obligatory stimulus for the activation of the nuclear enzyme poly(ADP-ribose) polymerase.
Poly(ADP-ribose) polymerase activation in turn depletes the intracellular concentration of its substrate NAD+, slowing the rate of glycolysis, electron transport, and ATP formation, and produces an ADP- ribosylation of the GAPDH. These processes result in acute endothelial dysfunction in diabetic blood vessels that, convincingly, also contributes to the development of diabetic complications. These new findings may explain why classic antioxidants, such as vitamin E, which work by scavenging already-formed toxic oxidation products, have failed to show beneficial effects on diabetic complications and may suggest new and attractive "causal" antioxidant therapy. New low-molecular mass compounds that act as SOD or catalase mimetics or L-propionyl- camitine and lipoic acid, which work as intracellular Superoxide scavengers, improving mitochondrial function and reducing DNA damage, may be good candidates for such a strategy, and preliminary studies support this hypothesis. This "causal" therapy would also be associated with other promising tools such as LY 333531 , PJ34, and FP15, which block the protein kinase β isoform, poly(ADP-ribose) polymerase, and peroxynitrite, respectively.
Insulin action is initiated through its binding to the cell surface receptor, initiating a series of signal transduction reactions, which stimulate various effectors to produce its physiological effects. Therefore, impairment of insulin signal transduction results in attenuation of insulin action and leads to insulin resistance resulting in type 2 diabetes mellitus. Because the molecular mechanisms of insulin resistance are still being elucidated, it is indispensable to establish in vitro models of basal and insulin-mediated signal transduction to clarify these mechanisms and suggest treatments where appropriate.
Evidence demonstrates that exogenously administered nitric oxide (NO) can induce insulin resistance in skeletal muscle. The modulatory effects of two NO donors, S-nitroso-N-acetyl D, L-penicillamine (SNAP) and S- nitrosoglutathione (GSNO) were investigated on the early events in insulin signaling in rat skeletal myocytes. Skeletal muscle is responsible for about 75% of whole body glucose metabolism, and insulin resistance is a characteristic feature of individuals with type Il diabetes mellitus. A number of intracellular defects in insulin action in muscle have been described, including decreased glucose transport and glucose phosphorylation and diminished glycogen synthase activity. A similar effect is observed in rodent model systems. It was also noted that acute treatment of skeletal myocytes by either GSNO or SNAP resulted in significantly reduced content of available IR-β for participating in insulin- mediate signal transduction. This could be a possible explanation for the decrease in insulin binding and insulin receptor sites observed in mononuclear leukocytes and erythocytes treated with these NO donors
There is increasing evidence that endogenous nitric oxide (NO) influences adipogenesis, lipolysis and insulin stimulated glucose uptake.
Endothelium derived nitric oxide is synthesized from the amino acid L- arginine by the endothelial isoform of nitric oxide synthase (NOS), yielding L-citrulline as a byproduct. Nitric oxide is labile with a short half- life (< 4 seconds in biological solutions). It is rapidly oxidised to nitrite and then nitrate by oxygenated haemoglobin before being excreted into the urine. Several co-factors are required for nitric oxide biosynthesis. These include nicotinamide adenine dinucleotide phosphate (NADPH),
flavin mononucleotide, flavin adenine dinucleotide, tetrahydrobiopterin (BH4), and calmodulin: Once synthesised, the nitric oxide diffuses across the endothelial cell membrane and enters the vascular smooth muscle cells where it activates guanylate cyclase, leading to an increase in intracellular cyclic Guanosine-3',5-Monophosphate (cGMP) concentrations4. As a second messenger, cGMP mediates many of the biological effects of nitric oxide including the control of vascular tone and platelet function. In addition, nitric oxide has other molecular targets, which include haem, or other iron centred proteins, DNA, and thiols. These additional reactions may mediate changes in functions of certain key enzymes or ion channels. Nitric oxide also interacts with enzymes of the respiratory chain including complex I and II, and aconitase, and through these effects alters tissue mitochondrial respiration. Interaction of nitric oxide with superoxide anion can attenuate physiological responses mediated by nitric oxide and produce irreversible inhibitory effects on mitochondrial function as a result of the formation of peroxynitrite (ONOO-), a powerful oxidant species.
NOSs are the only enzymes known to simultaneously require five bound cofactors/prosthetic groups: FAD, FMN, haem, tetrahydrobiopterin (BH4) and Ca2+-calmodulin (CaM). In mammals, three distinct genes encode NOS isozymes: neuronal (nNOS or NOS1), cytokine inducible (iNOS or NOS2) and endothelial (eNOS or NOS3).
The essential role of nitric oxide (NO) in normal physiology and its involvement in the pathophysiology of a variety of diseases render the compound an attractive therapeutic target. NO donor drugs are used in the treatment of hypotension and angina where abnormalities in the L-
arginine-nitric oxide pathway have been implicated. Overproduction of NO has been associated with a number of disease states including septic shock, inflammatory diseases, diabetes and its complications, ischaemia-reperfusion injury, adult respiratory distress syndrome, neurodegenerative diseases and allograft rejection. NO is produced by a group of enzymes, the nitric oxide synthases. Selective inhibition of the inducible isoform is one approach to the treatment of diseases where there is an overproduction of NO; an alternative approach is to scavenge or remove excess NO. A number of NO scavenger molecules have demonstrated pharmacological activity in disease models, particularly models of septic shock. These include organic molecules such as PTIO (2-pheny]-4,4,5,5-tetramethylimidazoline-1-oxy!-3-oxide), haemoglobin derivatives such as the pyridoxalated haemoglobin polyoxyethylene conjugate (PHP), low molecular weight iron compounds of diethylenetriaminepentaacetic acid and diethyldithiocarbamate and ruthenium polyaminocarboxylate complexes. The data suggest a potential role for NO scavengers in the treatment of NO mediated disease
Thus, while treating Diabetes, prevention of macro and microvascular complications is of paramount importance and therefore, Oral Hypoglycemic Agents such as Sulfonylureas and Biguanides alone may not suffice. The augmentation with Nitric Oxide Scavengers would ensure greater protection to the vasculature from the potential damage caused by a cascade of events following pronounced nitrosative stress. It's well known that conventionally used antioxidants do not have any perceptible role in neutralising the nitrosative stress and the Superoxide Anion.
However, since NO is a double edged weapon, it's important to guard against the deleterious effects. Hence it would be prudent to combine a NO-scaveger along with the above anti diabetic drug to ensure long- term safety of the products.
Objectives
An Objective of this invention is to treat Diabetes and prevent its complications by providing the Oral Hypoglycemic Agents, commonly known as, "Alphaglucosidase- Inhibitors". The invention embodies in itself the Claim for separate and individual drugs, that would include Acarbose and Miglitol as separate entities and separate set of inventions
Another Objective of this invention is to prevent the Diabetic complications produced due to excessive nitrosative stress by mitigating the deleterious effects of NO, with the combination/complexation of the Antidiabeti drugs with the NO scavengers, which would include PTIO, PHP, low molecular weight iron compounds of diethylenetriarninepentaacetic acid, diethyldithiocarbamate or ruthenium polyaminocarboxylate complexes or any other suitable NO scavenger
Another objective of this invention is to develop useful and convenient dosage levels and forms of such a combination therapeutic.
Yet another objective of this invention is to enhance individual effects of the components of this composition by their combination.
Summary
The invention embodies in itself 2 separate entities, each belonging to the class of drugs known as "Alphaglucosidase Inhibitors". Further, each active ingredient from the said class has been combined or complexated with NO Scavenger to prevent Diabetic Complications arising out of
' Nitrosative stress
The active ingredients are Alphaglucosidase Inhibitors, which block the action of alpha-glucosidase enzymes at the. brush border of the intestine.
The inactive ingredients are more or less the same for each of the compound: microcrystalline cellulose or hydroxypropyl methylcellulose, colloidal silicon dioxide, Magnesium stearate, Sodium, Starch, PEG and other appropriate agents
Detailed Description of the invention
The inhibition by the Alphaglucosidase Inhibitors slows the breakdown of dietary oligosaccharides and disaccharides. The delayed digestion of carbohydrates decreases post-prandial glucose concentrations. As monotherapy, alpha-glucosidase inhibitors lower FPG by 20 to 30 mg/dl and hemoglobin A1c by 0.7 to 1 %. Additionally, acarbose and miglitol decrease post-prandial glucose by 30 to 70 mg/dl. Acarbose and Miglitol have minimal effect on cholesterol and body weight.
The compositions are as follows:
1. Acarbose 25 to 100 mg per day in combination or complexated with NO-Scavenger
2. Miglitol 25 to 100 rng per day in combination or complexated with NO-Scavenger
Disclosure of Invention
While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth.
Claims
1. A therapeutic formulation comprising of Alphaglucosidase Inhibitors as active agents namely, Acarbose and Miglitol, characterized in that said Alphaglucosidase Inhibitors are combined or complexated with
NO Scavenger to prevent Diabetic Complications arising out of Nitrosative stress.
2. A therapeutic formulation as claimed in Claim 1 wherein NO scavenger would include PTIO, PHP1 low molecular weight iron compounds of diethylenetriaminepentaacetic acid, diethyldithiocarbamate or ruthenium polyaminocarboxylate complexes.
3. A therapeutic formulation as claimed in Claim 1 wherein microcrystalline cellulose or hydroxypropyl methylceliulose, colloidal silicon dioxide, Magnesium stearate, Sodium, Starch, PEG and other appropriate agents are added to the said Alphaglucosidase Inhibitors as inactive agent.
4. A therapeutic formulation as claimed in Claim 1 wherein Acarbose is combined or complexated with NO-Scavenger in a dosage range of 25 to 100 mg per day.
5. A therapeutic formulation as claimed in Claim 1 wherein Miglitol is combined or complexated with NO-Scavenger in a dosage range of 25 to 100 mg per day.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1761/CHE/2006 | 2006-09-26 | ||
IN1761CH2006 | 2006-09-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008038304A2 true WO2008038304A2 (en) | 2008-04-03 |
WO2008038304A3 WO2008038304A3 (en) | 2008-05-22 |
Family
ID=39230688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2007/000436 WO2008038304A2 (en) | 2006-09-26 | 2007-09-26 | Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008038304A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013115742A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Pharmaceutical composition comprising alpha-glucosidase inhibitor |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998011066A1 (en) * | 1996-09-10 | 1998-03-19 | Medinox, Inc. | Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications |
WO1998055453A1 (en) * | 1997-06-04 | 1998-12-10 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor |
WO1999066924A1 (en) * | 1998-06-23 | 1999-12-29 | Medinox, Inc. | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide |
US20020151540A1 (en) * | 2000-05-05 | 2002-10-17 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
WO2005027981A1 (en) * | 2003-09-17 | 2005-03-31 | Board Of Regents, The University Of Texas System | Mechanism-based targeted pancreatic beta cell imaging and therapy |
-
2007
- 2007-09-26 WO PCT/IN2007/000436 patent/WO2008038304A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998011066A1 (en) * | 1996-09-10 | 1998-03-19 | Medinox, Inc. | Polydithiocarbamate-containing macromolecules and the use thereof for therapeutic and diagnostic applications |
WO1998055453A1 (en) * | 1997-06-04 | 1998-12-10 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefor |
WO1999066924A1 (en) * | 1998-06-23 | 1999-12-29 | Medinox, Inc. | Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide |
US20020151540A1 (en) * | 2000-05-05 | 2002-10-17 | Medinox, Inc. | Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor |
WO2005027981A1 (en) * | 2003-09-17 | 2005-03-31 | Board Of Regents, The University Of Texas System | Mechanism-based targeted pancreatic beta cell imaging and therapy |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013115742A1 (en) * | 2012-01-31 | 2013-08-08 | Mahmut Bilgic | Pharmaceutical composition comprising alpha-glucosidase inhibitor |
Also Published As
Publication number | Publication date |
---|---|
WO2008038304A3 (en) | 2008-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sifuentes-Franco et al. | The role of oxidative stress, mitochondrial function, and autophagy in diabetic polyneuropathy | |
Omar et al. | Therapeutic effects of inorganic nitrate and nitrite in cardiovascular and metabolic diseases | |
Ebadi et al. | Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease | |
Kim-Shapiro et al. | Mechanisms of nitrite bioactivation | |
Obrosova | Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications | |
Nossaman et al. | Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications | |
Khatri et al. | It is rocket science–why dietary nitrate is hard to ‘beet’! Part I: twists and turns in the realization of the nitrate–nitrite–NO pathway | |
US6693094B2 (en) | Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus | |
EP1303304B1 (en) | Pharmaceutical combinations for treatment and prevention of diabetes mellitus | |
US6689385B2 (en) | Formulations for the treatment of insulin resistance and type 2 diabetes mellitus | |
Lange et al. | Role of nitric oxide in shock: the large animal perspective | |
Pereira et al. | Nitric oxide synthesis and biological functions of nitric oxide released from ruthenium compounds | |
Shinde et al. | Nitric oxide: a molecule of the millennium | |
Stefano et al. | Integrative medical therapy: examination of meditation's therapeutic and global medicinal outcomes via nitric oxide | |
Pierucci et al. | Nitric oxide modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders | |
EP1874285B1 (en) | Complementary compositions to reduce blood glucose levels and treat diabetes | |
Deboer et al. | Iron chelation in myocardial preservation after ischemia-reperfusion injury: the importance of pretreatment and toxicity | |
Bach | Targeting oxidative stress in stroke | |
KR100380634B1 (en) | Composition containing a dibenzocyclooctane lignan derivative for prevention or treatment of neurodegenerative disease | |
WO2008038304A2 (en) | Therapeutical formulation comprising an alpha-glucosidase inhibitor and a nitric oxide scavenger. | |
Wang et al. | Taurine inhibits ischemia/reperfusion-induced compartment syndrome in rabbits | |
EP0547558A1 (en) | Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation | |
WO2008038302A2 (en) | Therapeutic formulation comprising a sulfonylurea, metformin and a nitric oxide scavenger. | |
WO2008038303A2 (en) | Therapeutic formulation comprising a sulfonylurea, a thiazolidinedione and a nitric oxide scavenger. | |
Sharkawi | Inhibition of alcohol dehydrogenase by dimethyl formamide and dimethyl sulfoxide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07827585 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC DATED 22-09-2009 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07827585 Country of ref document: EP Kind code of ref document: A2 |